News | June 08, 2024
Briefs: Concord Biotech and Shelter Pharma
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
HaystackAnalytics is engaged in the business of developing genomic analysis software
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Subscribe To Our Newsletter & Stay Updated
